BridgeMD
New treatment option for Heart Failure
Official title Mechanisms of Semaglutide Therapy in Heart Failure Patients
ClinicalTrials.gov ID: NCT06541509
What this study is testing
What is Semaglutide?
Semaglutide is an investigational medicine, given as an once-weekly injection under the skin, being studied as a potential treatment for heart failure.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cells.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 to 80
You may be able to join if
- Age: 20-80 years
- Presence of heart failure
- Body-mass index 27 kg/m2 or greater
- Stable optimally tolerated dosages of heart failure therapies for 3 months
- N-terminal pro B-type natriuretic peptide levels \>350 pg/mL
You likely can't join if
- Presence of type 1 or type 2 diabetes or glycated haemoglobin higher than 6.5%
- Pregnancy or potential to become pregnant
- Cancer
- Liver dysfunction (aspartate aminotransferase and/or alanine aminotransferase \> 3 times upper limits of normal or total bilirubin greater than 1.5...
- Renal dysfunction (estimated glomerular filtration rate less than 25 mL/min/1.73 m2)
- Hospitalization in the past 3 months for reasons other than heart failure
See the full eligibility criteria
- Age: 20-80 years
- Presence of heart failure
- Body-mass index 27 kg/m2 or greater
- Stable optimally tolerated dosages of heart failure therapies for 3 months
- N-terminal pro B-type natriuretic peptide levels \>350 pg/mL
- Presence of type 1 or type 2 diabetes or glycated haemoglobin higher than 6.5%
- Pregnancy or potential to become pregnant
- Cancer
- Liver dysfunction (aspartate aminotransferase and/or alanine aminotransferase \> 3 times upper limits of normal or total bilirubin greater than 1.5 times upper limits of normal)
- Renal dysfunction (estimated glomerular filtration rate less than 25 mL/min/1.73 m2)
- Hospitalization in the past 3 months for reasons other than heart failure
- New York Heart Association (NYHA) functional class I or functional class IV symptoms.
- Prior or planned bariatric surgery
- Self-reported change in body weight \>11 lbs (5 kg) within 3 months before enrollment
- Acute or chronic infection
The study team makes the final eligibility decision.
Where it's taking place
- Palo Alto, California, United States
- Stanford, California, United States
- Ljubljana, Slovenia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 20 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Palo Alto, California, United States; Stanford, California, United States; Ljubljana, Slovenia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.